Current best evidence for clinical care (more info)
OBJECTIVE: To assess the performance of the SARS-CoV-2 antigen rapid lateral flow test (LFT) versus polymerase chain reaction testing in the asymptomatic general population attending testing centres.
DESIGN: Observational cohort study.
SETTING: Community LFT pilot at covid-19 testing sites in Liverpool, UK.
PARTICIPANTS: 5869 asymptomatic adults (=18 years) voluntarily attending one of 48 testing sites during 6-29 November 2020.
INTERVENTIONS: Participants were tested using both an Innova LFT and a quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR) test based on supervised self-administered swabbing at testing sites.
MAIN OUTCOME MEASURES: Sensitivity, specificity, and predictive values of LFT compared with RT-qPCR in an epidemic steady state of covid-19 among adults with no classic symptoms of the disease.
RESULTS: Of 5869 test results, 22 (0.4%) LFT results and 343 (5.8%) RT-qPCR results were void (that is, when the control line fails to appear within 30 minutes). Excluding the void results, the LFT versus RT-qPCR showed a sensitivity of 40.0% (95% confidence interval 28.5% to 52.4%; 28/70), specificity of 99.9% (99.8% to 99.99%; 5431/5434), positive predictive value of 90.3% (74.2% to 98.0%; 28/31), and negative predictive value of 99.2% (99.0% to 99.4%; 5431/5473). When the void samples were assumed to be negative, a sensitivity was observed for LFT of 37.8% (26.8% to 49.9%; 28/74), specificity of 99.6% (99.4% to 99.8%; 5431/5452), positive predictive value of 84.8% (68.1% to 94.9%; 28/33), and negative predictive value of 93.4% (92.7% to 94.0%; 5431/5814). The sensitivity in participants with an RT-qPCR cycle threshold (Ct) of <18.3 (approximate viral loads >106 RNA copies/mL) was 90.9% (58.7% to 99.8%; 10/11), a Ct of <24.4 (>104 RNA copies/mL) was 69.4% (51.9% to 83.7%; 25/36), and a Ct of >24.4 (<104 RNA copies/mL) was 9.7% (1.9% to 23.7%; 3/34). LFT is likely to detect at least three fifths and at most 998 in every 1000 people with a positive RT-qPCR test result with high viral load.
CONCLUSIONS: The Innova LFT can be useful for identifying infections among adults who report no symptoms of covid-19, particularly those with high viral load who are more likely to infect others. The number of asymptomatic adults with lower Ct (indicating higher viral load) missed by LFT, although small, should be considered when using single LFT in high consequence settings. Clear and accurate communication with the public about how to interpret test results is important, given the chance of missing some cases, even at high viral loads. Further research is needed to understand how infectiousness is reflected in the viral antigen shedding detected by LFT versus the viral loads approximated by RT-qPCR.
| Discipline / Specialty Area | Score |
|---|---|
| Infectious Disease | |
| Public Health | |
| Hospital Doctor/Hospitalists | |
| Internal Medicine | |
Most hospitals have altered their asymptomatic COVID-19 testing screening protocols to take advantage of the highly effect nature of existing vaccines, and relatively few hospitalists are given the choice between multiple platforms for testing asymptomatic patients. My concern is that the relatively low sensitivity (only 40%!) may be unsuitable for most screening purposes in an inpatient setting.
Well done and well presented comparison of the sensitivity of the Innova SARS-CoV-2 antigen rapid lateral flow test against PCR in 5,869 asymptomatic adults attending one of 48 testing sites in November 2020. Most infectious diseases attendings probably already understand that the sensitivity of rapid tests is proportional to the viral load in the sample.